Zobrazeno 1 - 10
of 464
pro vyhledávání: '"63"'
Autor:
Andrea Eisen, Danilo Giffoni M. M. Mata, Sonal Gandhi, Abdullah Ma Al-Humiqani, Katarzyna J. Jerzak, Alia Thawer, Maria Luisa Romero Lagunes, Rossanna C. Pezo, Faisal Sickandar, Maureen E. Trudeau, Neda Stjepanovic, Anthony Lott, Ellen Warner
Publikováno v:
Cancer Research. 81:PS10-54
Background: For Hormonal Receptor positive/HER2 negative (HR+/HER2-) metastatic Breast Cancer (mBC) the optimal treatment post-progression on a CDK4/6 inhibitor is still not defined. We aim to identify real-world patterns of systemic treatment choice
Autor:
Baha' Sharaf, Rawan Mustafa, Razan Mansour, Hikmat Abdel-Razeq, Maryam El-Atrash, Faris Tamimi
Publikováno v:
Cancer Research. 81:PS7-73
Introduction: The Syrian crisis, started in 2011, has had a profound impact on the entire region. Jordan, a low-middle income country with limited resources is ranked first in the region in relation to the number of refugees hosted. The latest nation
Autor:
Thibaut Sanglier, D. Tesarowski, Patricia Luhn, Eleonora Restuccia, Anita Fung, Carlos Flores, Preet K. Dhillon, Devin Incerti, Vincent Antao
Publikováno v:
Cancer Research. 81:PS10-20
OBJECTIVES Over the last decade, new treatment options have transformed the standard of care for patients (pts) with HER2-positive EBC and the treatment landscape continues to evolve. The primary objectives of our study were (1) to describe and compa
Autor:
Rohini Hawaldar, Sudeep Gupta, Rajendra A. Badwe, Vani Parmar, Bipin Bandre, Karishma Kirti, Seema Gulia, Vaibhav Vanmali, Shalaka Joshi, Nita S. Nair, Tanuja Shet, Sridevi Murali
Publikováno v:
Cancer Research. 81:PS14-23
Background: Ductal carcinoma in situ (DCIS) identified by screening mammography accounts for 20% of breast cancer diagnoses, and microinvasion (DCIS-M) is found in 5%-10%. There are no defined treatment guidelines for palpable DCIS or DCIS-M. The rol
Autor:
Eleonora Pagan, Silvia Dellapasqua, Monica Iorfida, Claudia Sangalli, Vincenzo Bagnardi, Emilia Montagna, Loredana Sansonno, N. Bianco, Mara Negri, Anna Cardillo, G.M. Campennì, Monica Milano, Manuelita Mazza, Angela Sciandivasci, Giuseppe Cancello, Ana Paula De Maio, Elisabetta Munzone
Publikováno v:
Cancer Research. 80:P2-14
Background Adjuvant chemotherapy regimens for ‘Luminal B’ disease usually include anthracycline-based regimens with or without taxanes. However, several patients are reluctant to receive chemotherapy because of toxic side-effects, especially alop
Autor:
Hae Hyun Jung, Seok Won Kim, Yeon Hee Park, Kyunghee Park, Ji-Yeon Kim, Jeong Eon Lee, Jonghan Yu, Se Kyung Lee, Seok Jin Nam
Publikováno v:
Cancer Research. 80:P1-10
Introduction: Neoadjuvant chemotherapy (NAC) enables curative surgery and deprives micrometastasis in locally advanced breast cancer (LABC). Indeed, response of NAC, representatives of pathologic complete response (pCR) as well as residual cancer bur
Autor:
David Miles, Matthew Kent, Kenneth Russell, Mary K Downer, Patricia Luhn, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 80:P2-15
Background: Corticosteroids (CS) have immunosuppressive properties that may diminish the efficacy of cancer immunotherapy (CIT). In retrospective analyses of clinical trial data, the use of CS for immune-mediated adverse events after starting CIT doe
Autor:
I. Vanden Bempt, Ines Nevelsteen, Guiseppe Floris, J Goyens, H. Wildiers, K Punie, E Van Nieuwenhuysen, Patrick Neven, A Smeets, Ignace Vergote, S Vander Borght, Sileny Han
Publikováno v:
Cancer Research. 79:P3-08
Background: Clinical next-generation sequencing (NGS) has opened new perspectives on genome-driven therapy for metastatic breast cancer (MBC) through the identification of recurrent driver mutations. However, therapeutic relevance of the detection of
Autor:
Maxwell P. Lee, Albert J. Kovatich, H Hu, Y Zhang, P-K Raj-Kumar, Craig D. Shriver, Howard H. Yang, J Liu
Publikováno v:
Cancer Research. 79:P2-08
Background: Basal-like breast cancer (BLBC) have poor prognosis. Molecular similarities have been reported between BLBC and high grade serous ovarian cancer (HGSOC). To date, there have been no prognostic biomarkers specifically developed for BLBC or
Publikováno v:
Cancer Research. 79:P3-10
Background: Two recent randomized phase 3 trials have demonstrated that treatment with PARP inhibitors results in an improvement in progression-free survival (PFS) in metastatic, BRCA-mutant, HER2-negative breast cancer patients. We have previously i